Mind The Gap: Different Views Of Success May Drive Large Differences In Estimates Of Pharma Value
The success rates of late-stage molecules may prove to be higher than current analyst estimates; historical data suggests the biopharma industry has been fairly resilient in its ability to deliver its R&D pipeline while adapting to challenges.
You may also be interested in...
Blockbuster drugs are not going away but as science and market conditions continue to evolve and unmet needs shift to new territories, their profile is likely to change again. Companies can use strategies to offset the potential shortcomings of the new blockbuster model and improve their chances of becoming the successful players of tomorrow.
Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.